Investigación del potencial neuroprotector de los cannabinoides en un modelo murino de ataxia espinocerebelosa tipo 3
- María Luz Hernández Galvez Zuzendaria
- María del Sagrario Gómez Ruiz Zuzendaria
Defentsa unibertsitatea: Universidad Complutense de Madrid
Fecha de defensa: 2022(e)ko apirila-(a)k 27
- Guillermo Velasco Díez Presidentea
- Raquel Gómez de Heras Idazkaria
- Nuria del Olmo Izquierdo Kidea
- Emilio Ambrosio Flores Kidea
- Fernando Berrendero Diaz Kidea
Mota: Tesia
Laburpena
Spinocerebellar ataxia type 3 (SCA-3) is a neurodegenerative disease of genetic origin. This disease is caused by a pathological increase in the number of CAG triplet repeats in the gene encoding ataxin-3. The most characteristic symptom of this disease is the onset of progressive ataxia, which is usually accompanied by a wide range of symptoms including alterations in some cognitive functions. As in many other neurodegenerative diseases, no effective treatment for SCA-3 has been developed to date, making it necessary to search for possible therapeutic targets.The endocannabinoid system (ECS) is a neuromodulatory system whose activation can trigger several neuroprotective responses. It has been shown that in SCA-3, as in other neurodegenerative diseases, some of the classical elements of the ECS, like the CB1 and CB2 receptors, as well as the degradation enzymes FAAH and MAGL, are deregulated. Therefore, ECS is positioned as a promising therapeutic option for this pathology...